Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary

  Ovarian Neoplasms

  Free Subscription


13.01.2020

2 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
2 Gynecol Oncol
1 Histopathology
1 Int J Cancer
1 Int J Gynecol Pathol
3 Int J Oncol
3 Obstet Gynecol
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. YUE H, Wang J, Chen R, Hou X, et al
    Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer.
    BMC Cancer. 2019;19:1266.
    PubMed     Text format     Abstract available

  2. AHN JI, Yoo JY, Kim TH, Kim YI, et al
    G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer.
    BMC Cancer. 2019;19:810.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  3. WANG Z, Gao J, Ohno Y, Liu H, et al
    Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
    Cancer Chemother Pharmacol. 2020 Jan 6. pii: 10.1007/s00280-019-04025.
    PubMed     Text format     Abstract available


    Cancer Lett

  4. SHENG R, Li X, Wang Z, Wang X, et al
    Circular RNAs and their Emerging Roles as Diagnostic and Prognostic Biomarkers in Ovarian Cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30665.
    PubMed     Text format     Abstract available


    Cancer Res

  5. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  6. ALVAREZ SECORD A, Bell Burdett K, Owzar K, Tritchler D, et al
    Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0226.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  7. REISER E, Aust S, Seebacher V, Reinthaller A, et al
    Gamma-glutamyltransferase as a preoperative differential diagnostic marker in patients with adnexal mass.
    Eur J Obstet Gynecol Reprod Biol. 2019;239:16-20.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  8. BREWER M, Angioli R, Scambia G, Lorusso D, et al
    Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
    PubMed     Text format     Abstract available

  9. SALMINEN L, Nadeem N, Jain S, Grenman S, et al
    A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
    PubMed     Text format     Abstract available


    Histopathology

  10. PETERS EEM, Bartosch C, McCluggage WG, Genestie C, et al
    Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.
    Histopathology. 2019;75:128-136.
    PubMed     Text format     Abstract available


    Int J Cancer

  11. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    PubMed     Text format     Abstract available


    Int J Gynecol Pathol

  12. ANGELICO G, Santoro A, Arciuolo D, Valente M, et al
    Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma.
    Int J Gynecol Pathol. 2020;39:e2-e3.
    PubMed     Text format    


    Int J Oncol

  13. LEE SY, Kwon J, Woo JH, Kim KH, et al
    Bcl2l10 mediates the proliferation, invasion and migration of ovarian cancer cells.
    Int J Oncol. 2019 Dec 23. doi: 10.3892/ijo.2019.4949.
    PubMed     Text format     Abstract available

  14. FENG Y, Tang Y, Mao Y, Liu Y, et al
    PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4958.
    PubMed     Text format     Abstract available

  15. BU H, Li Y, Jin C, Yu H, et al
    Overexpression of PRC1 indicates a poor prognosis in ovarian cancer.
    Int J Oncol. 2020 Jan 10. doi: 10.3892/ijo.2020.4959.
    PubMed     Text format     Abstract available


    Obstet Gynecol

  16. BRISTOW RE, Chang J, Villanueva C, Ziogas A, et al
    A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
    Obstet Gynecol. 2020 Feb 9. doi: 10.1097/AOG.0000000000003665.
    PubMed     Text format     Abstract available

  17. BULL PHELPS SL, Jackson-Moore LA
    Ovarian Cancer Care in the Affordable Care Act Era: Ovarian Cancer Breaking the Silence?
    Obstet Gynecol. 2020 Feb 9. doi: 10.1097/AOG.0000000000003679.
    PubMed     Text format    

  18. SMITH AJB, Fader AN
    Association of the Affordable Care Act With Ovarian Cancer Care.
    Obstet Gynecol. 2020 Feb 9. doi: 10.1097/AOG.0000000000003630.
    PubMed     Text format     Abstract available


    PLoS One

  19. MIAO R, Badger TC, Groesch K, Diaz-Sylvester PL, et al
    Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    PLoS One. 2020;15:e0227707.
    PubMed     Text format     Abstract available

  20. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: